Company intelligence / Profile preview
NewVac
Khimki/Moscow area, Moscow Region/Moscow Oblast, Russianewvac.ru ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NewVac has completed a Phase II clinical trial of quisinostat, an oral selective histone deacetylase inhibitor, in combination with chemotherapy for platinum-resistant ovarian cancer. The study demonstrated a high objective response rate of 51.6%, exceeding protocol expectations, with favorable safety and tolerability. Median progression-free survival was reported at seven months. The company is also developing personalized therapeutic vaccines and other oncology assets.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Small moleculeVaccine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Janssen Pharmaceutica NV / Johnson & Johnson Group – license/co-development agreement for quisinostatAgenus – collaboration on personalized vaccines
Beyond the preview
Go deeper on NewVac.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NewVac.